You are required to be logged in to access the full website
Click here if you have forgotten your username or password
Therapy Areas
18 May 2026 - Biopharmaceutical company AstraZeneca plc (LSE: AZN) (STO: AZN) (NYSE: AZN) reported on Monday that it has received US Food and Drug Administration approval for Baxfendy (baxdrostat), the first and only aldosterone synthase inhibitor fo...
18 May 2026 - CTC intelligence company CelLBxHealth plc (AIM: CLBX) announced on Monday that it has entered a collaboration with AdventHealth, a US-based faith-based health system, to use its Parsortix platform in two clinical studies focused on mini...
18 May 2026 - Biopharmaceutical company GSK plc (LSE: GSK) (NYSE: GSK) disclosed on Monday that Japan's Ministry of Health, Labour and Welfare has expanded approval for its RSV vaccine, Arexvy, to include adults aged 18 to 49 years who are at in...
18 May 2026 - Atisama Therapeutics (formerly Rage Bio), an Australian clinical-stage biotechnology company, on Friday reported progress in the Phase 1 study of its lead candidate, RB042.The RB042 Phase 1 study (RB042_1001), evaluating RB042 in health...
18 May 2026 - Racura Oncology, an Australian Phase 3 stage clinical biopharmaceutical company, announced on Friday that the independent Safety Review Committee (SRC) has completed its review of safety data from Cohort one in the ongoing CPACS clinica...
15 May 2026 - SN BioScience Inc, a clinical-stage biotechnology company based in South Korea, announced on Thursday that it has started the first patient dosing in its global Phase 1b/2 clinical trial evaluating SNB-101 (API: SN-38), a nanoparticle a...